Coronary disease & ACSTrial design
Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial
- investigator-initiated, multicenter, open-label, randomized, superiority study
- design and rationale (trial protocol)
- 1:1 randomization
Study context
- Population
- Patients with advanced chronic kidney disease (CKD) (estimated glomerular filtration rate <45 mL/min/1.73 m²) undergoing percutaneous coronary intervention (PCI) with contemporary drug-eluting stentsplanned enrolment
- Participants
- 900 patients
- Planned comparison
- abbreviated vs a standard dual antiplatelet therapy (DAPT) strategy
- Primary endpoint
- net adverse clinical events:
- Composite of all-cause death
- Myocardial infarction
- Stent thrombosis
- Stroke
- Major bleeding according to the Bleeding Academic Research Consortium criteria
- Follow-up
- 1 year
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial. Am Heart J. Published 1 April 2026. doi:10.1016/j.ahj.2026.107437
Summarised from the published abstract; every number is checked against it